Astrazeneca

FromAstraZeneca ([email protected])
Subject (48)Enhertu granted Priority Review for HER2-low mBC
Preheader (93)Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Typography
Arial
Colors
Text Analysis
Body Words228
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px780 px
X-Spam Score0.5
Preheader OptimizedNo
Timing
Day of WeekTuesday
TimeOvernight

Enhertu granted Priority Review for HER2-low mBC

Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Enhertu granted Priority Review for HER2-low mBC